13F Holdings
中文EN

EWTX Edgewise Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1710072 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY742.1%
TTM EPS YoY633.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE92.1%
ROA85.4%
ROIC (approx.)-16.6%
Asset turnover—

Leverage & solvency

Liabilities / assets8.3%
Debt / equity0.00x
Current ratio12.30x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.20x
Accruals ratio102.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$151.39M$126.97M$90.91M$54.03M$32.19M
SG&A expense$40.02M$31.87M$23.45M$17.63M$11.03M
Operating income-$191.41M-$158.83M-$114.36M-$71.66M-$43.22M
Pretax income-$167.80M-$133.80M-$100.20M——
Income tax$4,000$3,000$4,000$0$0
Net income-$167.79M-$133.81M-$100.16M-$67.64M-$42.81M
EBITDA-$189.32M-$156.76M-$112.81M-$71.29M-$42.94M
EPS (basic)-1.63-1.45-1.57-1.26-1.14
EPS (diluted)-1.63-1.45-1.57-1.26-1.14
Weighted avg. shares (diluted)102.93M92.41M63.72M53.59M37.53M
Balance sheet
Cash & equivalents$61.15M$41.67M$86.10M$21.99M$15.57M
Current assets$543.38M$475.48M$327.00M$357.00M$283.77M
PP&E, net$7.83M$9.50M$10.44M$8.53M$912,000
Total assets$552.60M$486.82M$340.04M$367.10M$285.23M
Current liabilities$27.37M$23.86M$16.77M$16.59M$10.52M
Total liabilities$30.35M$27.60M$21.20M$20.39M$10.85M
Shareholders' equity$522.26M$459.22M$318.83M$346.72M$274.38M
Shares outstanding106.25M94.84M70.45M63.26M49.50M
Cash flow statement
Operating cash flow-$143.82M-$109.03M-$91.95M-$52.63M-$33.51M
Capital expenditure$256,000$1.31M$5.75M$5.55M$668,000
Free cash flow-$144.07M-$110.34M-$97.69M-$58.18M-$34.17M
Investing cash flow-$32.79M-$184.66M$102.89M-$70.58M-$242.23M
Financing cash flow$196.09M$249.25M$53.17M$129.64M$186.38M
Depreciation & amortization$2.08M$2.07M$1.55M$368,000$272,000
Stock-based compensation$34.75M$24.71M$17.56M$10.92M$4.40M

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.